Physician profile
Tanja Phillips
NPI 1801662382
$1,441.56
in general payments reported to CMS, 2019-2025
19 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $413 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $259.78 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $229.57 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Esperion Therapeutics, INC. | $220.45 | 2024-2025 | Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $144.47 | 2024-2025 | |
| Abbvie INC. | $113.05 | 2024-2025 | |
| Pfizer INC. | $80.93 | 2025 | |
| Merck Sharp & Dohme LLC | $50.16 | 2024-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Janssen Pharmaceuticals, INC | $44.50 | 2024-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.03 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $39.98 | 2025 | Veozah |
| Lilly USA, LLC | $36.78 | 2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $35.10 | 2024 | Inspire |
| Corcept Therapeutics | $29.69 | 2025 | Korlym |
| Eisai INC. | $27.93 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.46 | 2025 | Keveyis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.01 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $18.63 | 2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $14.35 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $13.69 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanja Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.